Portal de Periódicos da CAPES

Statin Wars-Emphasis on Potency vs Event Reduction and Safety?

2007; Elsevier BV; Volume: 82; Issue: 5 Linguagem: Inglês

10.4065/82.5.539

1942-5546

Carl J. Lavie, Richard V. Milani, James H. O’Keefe,

Health Systems, Economic Evaluations, Quality of Life

Considerable evidence during the past 3 decades from epidemiologic, serial angiographic, and major randomized clinical trials has established the importance of low-density lipoprotein cholesterol (LDL-C) in modulating atherosclerosis, particularly coronary artery disease (CAD).1 More recently, the constellation of evidence has shown the clinical value of reducing LDL-C levels, even lower than that recommended by prominent guidelines.1–4